Related Experiment Video
Updated: Feb 2, 2026

Evaluating the Role of Mitochondrial Function in Cancer-related Fatigue
Published on: May 17, 2018
The Role of PI3K in Met Driven Cancer: A Recap
Alexia Hervieu1,2, Stéphanie Kermorgant2
1Signal Transduction and Molecular Pharmacology Team, Cancer Therapeutics Division, Institute of Cancer Research, Sutton, United Kingdom.
Abstract:
The Receptor Tyrosine Kinase (RTK) Met, overexpressed or mutated in cancer, plays a major role in cancer progression and represents an attractive target for cancer therapy. However RTK inhibitors can lead to drug resistance, explaining the necessity to develop therapies that target downstream signaling. Phosphatidylinositide 3-kinase (PI3K) is one of the most deregulated pathways in cancer and implicated in various types of cancer. PI3K signaling is also a major signaling pathway downstream of RTK, including Met. PI3K major effectors include Akt and "mechanistic Target of Rapamycin" (mTOR), which each play key roles in numerous and various cell functions. Advancements made due to the development of molecular and pharmaceutical tools now allow us to delve into the roles of each independently. In this review, we summarize the current understanding we possess of the activation and role of PI3K/Akt/mTOR, downstream of Met, in cancer.
Insights
Met receptor tyrosine kinase (RTK) signaling is crucial in cancer. Targeting downstream Phosphatidylinositide 3-kinase (PI3K)/Akt/mTOR pathways offers new therapeutic strategies against Met-driven cancers and resistance.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Signaling Pathways
Background:
- The Met receptor tyrosine kinase (RTK) is frequently altered in cancer, driving tumor progression.
- Met signaling activates crucial downstream pathways, including Phosphatidylinositide 3-kinase (PI3K).
- Drug resistance to RTK inhibitors necessitates targeting downstream effectors like PI3K/Akt/mTOR.
Purpose of the Study:
- To review the activation and role of the PI3K/Akt/mTOR pathway downstream of Met in cancer.
- To highlight the significance of these pathways in Met-driven oncogenesis.
- To discuss the implications for developing novel cancer therapies.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of molecular mechanisms of Met signaling.
- Examination of PI3K/Akt/mTOR pathway components and their functions.
Main Results:
- Met receptor activation leads to the deregulation of the PI3K/Akt/mTOR pathway.
- This pathway controls key cellular processes including proliferation, survival, and metabolism.
- Understanding these interactions is vital for therapeutic intervention.
Conclusions:
- The PI3K/Akt/mTOR pathway is a critical mediator of Met-driven cancer.
- Targeting this pathway offers a promising strategy to overcome resistance to Met inhibitors.
- Further research into these molecular players can lead to improved cancer treatments.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
ATP Driven Pumps I: An Overview
There are four main types of ATP-driven pumps - P-type, V-type, F-type, and ABC transporter. All these pumps are of varying complexities and...
Role of Septins
Cellular Functions of Septins
Recent studies have revealed the multifaceted roles of septins in various cellular processes such as cytokinesis, ciliogenesis, and neurogenesis. Septins act as scaffolds and...
The Role of Culture
Xylem and Transpiration-driven Transport of Resources
ATP Driven Pumps II: P-type Pumps
A typical P-type pump has three cytosolic domains: nucleotide-binding (N), phosphorylation (P), and activator (A) domains. These domains are connected to the membrane-spanning helices by short amino acid segments. ATP hydrolysis and covalent phosphoenzyme intermediate formation are crucial parts of the catalytic cycle. At the highly...

